Abstract

Background: Aortic stenosis (AS) is one of the most common valvular heart diseases. On 78% of patients with aortic stenosis have comorbid hypertension. Until now guideline treatment of a patient with hypertension in aortic stenosis is still controversial. Beta-blocker is an antihypertensive drug that has no known good or bad risk in aortic stenosis. Objective: To evaluate the impact of beta-blocker as a treatment for hypertension in patients with aortic stenosis Methods: A randomized control trial and other studies comparing outcomes of patient aortic stenosis using beta-blocker were performed through PubMed and Cochrane. The primary outcome was a risk for all-cause mortality. Risk ratios (RRs) were calculated using a random-effect model with a corresponding 95% confidence interval. Result: Four studies with 2.398 patients were included. There were no significant differences between intervention beta-blocker or not for the risk of all-cause mortality (RR 0.82, 95% CI 0.53 to 1.28, p=0.38), and other outcome such us change of ejection fraction left ventricular (SMD 0.02, 95% CI -0.10 to 0.14, p=0.73) and left ventricular mass (SMD -0.03, 95% CI -0.15 to 0.09, p=0.62). Conclusion: Intervention anti-hypertensive with beta-blocker not associated with outcome in patient with aortic stenosis.

Concepts :

Access to Document

SDGs

Citations by Year